Skip to content

Integra LifeSciences IART Finite Lived Intangible Assets Amortization Expense After Year Five

Finite Lived Intangible Assets Amortization Expense After Year Five at other companies

ICU Medical logo
ICU MedicalICUI

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's finite lived intangible assets amortization expense after year five.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's finite lived intangible assets amortization expense after year five?
Integra LifeSciences (IART) reported finite lived intangible assets amortization expense after year five of $359.9M in Q1 2026.
How has Integra LifeSciences's finite lived intangible assets amortization expense after year five changed year-over-year?
Integra LifeSciences's finite lived intangible assets amortization expense after year five decreased by 18.1% year-over-year, from $439.2M to $359.9M.